Catalent (CTLT) : Traders are bullish on Catalent (CTLT) as it has outperformed the S&P 500 by a wide margin of 3.82% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.59%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.56% in the last 1 week, and is up 4.21% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Catalent, Inc. has dropped 11.94% during the last 3-month period . Year-to-Date the stock performance stands at 0.8%. The stock has recorded a 20-day Moving Average of 0.56% and the 50-Day Moving Average is 5.54%.
Catalent (NYSE:CTLT): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $24.90 and $24.82 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $25.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $25.23, notching a gain of 0.88% for the day. The total traded volume was 728,545 . The stock had closed at $25.01 on the previous day.
Also, Major Brokerage house, Wells Fargo upgrades its ratings on Catalent (NYSE:CTLT). According to the latest information available, the shares are now rated Outperform by the analysts at the agency. Previously, the analysts had a Market Perform rating on the shares. The rating by the firm was issued on June 21, 2016.
Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.